4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
"This is a historic moment for 4DMT as we become a Phase 3 company following our initiation of the 4FRONT-1 clinical trial,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
Top Stocks Will Dominate Despite Tariffs—Including This One
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tom Yeung here with today’s Smart Money. Do you remember what ...
4D Molecular Therapeutics, Inc.: 4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...
Alienware AW2725Q QD-OLED Review: Pretty Picture, but Pricey
It is a beautiful-looking monitor with crisp visuals and solid built, though it comes for a pretty penny.
Apple Mac Studio (2025, M4 Max)
The base model of the 2025 Mac Studio comes with a 14-core version of the M4 Max chip, a 32-core GPU, and a 16-core Neural ...
Apple Mac Studio Review: A Hefty Little Powerhouse
The Apple Mac Studio comes bearing ridiculous power far beyond the needs of the average consumer with a price to match.
Alienware 27 4K QD-OLED (AW2725Q)
Alienware claims that the AW2725Q offers the highest pixel density on a QD-OLED monitor of this size. At 166 pixels per inch ...
Kodiak Sciences Completes Enrollment In Second Registrational Trial Of Tarcocimab In Patients With Diabetic Retinopathy
Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. <li /> GLOW2 study design mirrors GLOW1 study, ...
How do Intel's new commercial processors stack up against the best from AMD and Qualcomm?
Intel just announced an expansion of its Core Ultra (Series 2) processor family of devices to include more chips with vPro.
Molecular Partners AG (NASDAQ:MOLN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...
Kodiak Sciences Inc.: Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy
Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and ...